NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally.[ Read More ]
The intrinsic value of one NAOV stock under the base case scenario is HIDDEN Compared to the current market price of 0.639 USD, NanoVibronix, Inc. is HIDDEN
Current Assets | 6.49 M |
Cash & Short-Term Investments | 3.28 M |
Receivables | 425 K |
Other Current Assets | 2.78 M |
Non-Current Assets | 187 K |
Long-Term Investments | 0 |
PP&E | 12 K |
Other Non-Current Assets | 175 K |
Current Liabilities | 2.45 M |
Accounts Payable | 138 K |
Short-Term Debt | 10 K |
Other Current Liabilities | 2.31 M |
Non-Current Liabilities | 232 K |
Long-Term Debt | 0 |
Other Non-Current Liabilities | 232 K |
Revenue | 2.28 M |
Cost Of Revenue | 746 K |
Gross Profit | 1.54 M |
Operating Expenses | 4.97 M |
Operating Income | -3.44 M |
Other Expenses | 275 K |
Net Income | -3.71 M |
Net Income | -3.71 M |
Depreciation & Amortization | 1 K |
Capital Expenditures | -1 K |
Stock-Based Compensation | 293 K |
Change in Working Capital | -322 K |
Others | 627 K |
Free Cash Flow | -3.6 M |
Date | Value | Insider | Amount | Avg Price |
---|---|---|---|---|
1 year ago
Jan 05, 2023
|
Bought 12.5 K USD
|
MIKA THOMAS
Director |
+ 50000
|
0.25 USD |
2 years ago
Jun 15, 2022
|
Bought 23.8 K USD
|
FASHEK CHRISTOPHER M
director: |
+ 40000
|
0.5957 USD |
4 years ago
Nov 20, 2019
|
Bought 50 K USD
|
FASHEK CHRISTOPHER M
Director |
+ 25000
|
2 USD |
2 years ago
Jun 14, 2022
|
Bought 2.3 K USD
|
BROWN STEPHEN RUSSELL
Chief Financial Officer |
+ 4000
|
0.5739 USD |
2 years ago
Jun 01, 2022
|
Bought 1.38 K USD
|
Cassirer Aurora
director: |
+ 2000
|
0.69 USD |
4 years ago
Sep 29, 2020
|
Bought 7.89 K USD
|
FASHEK CHRISTOPHER M
Director |
+ 10000
|
0.7887 USD |